Last reviewed 2026-04-23 · How we verify

beta-II-agonist, inhale steroid

This combination therapy relaxes airway smooth muscle via beta-2 adrenergic stimulation while simultaneously reducing airway inflammation through inhaled corticosteroid activity.

This combination therapy relaxes airway smooth muscle via beta-2 adrenergic stimulation while simultaneously reducing airway inflammation through inhaled corticosteroid activity. Used for Asthma maintenance and reliever therapy, Chronic obstructive pulmonary disease (COPD).

At a glance

Mechanism of action

Beta-2 agonists bind to beta-2 adrenergic receptors on airway smooth muscle, causing bronchodilation and rapid symptom relief. Inhaled corticosteroids suppress local airway inflammation by inhibiting inflammatory mediators and immune cell activation. Together, this dual mechanism provides both acute bronchodilation and chronic anti-inflammatory control in obstructive airway disease.

Approved indications

• Asthma maintenance and reliever therapy
• Chronic obstructive pulmonary disease (COPD)

Common side effects

• Tremor
• Headache
• Palpitations
• Oral candidiasis
• Nervousness/anxiety

Key clinical trials

• A Comparison of Symbicort® Single Inhaler Therapy and Conventional Best Practice for the Treatment of Persistent Asthma (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• beta-II-agonist, inhale steroid CI brief — competitive landscape report
• beta-II-agonist, inhale steroid updates RSS · CI watch RSS
• AstraZeneca portfolio CI